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Background. Traditional imaging techniques for the localization and monitoring of bacterial infections, although reasonably
sensitive, suffer from a lack of specificity. This is particularly true for musculoskeletal infections. Bacteria possess a thymidine
kinase (TK) whose substrate specificity is distinct from that of the major human TK. The substrate specificity difference has
been exploited to develop a new imaging technique that can detect the presence of viable bacteria. Methodology/Principal
Findings. Eight subjects with suspected musculoskeletal infections and one healthy control were studied by a combination of
[
124I]FIAU-positron emission tomography and CT ([
124I]FIAU-PET/CT). All patients with proven musculoskeletal infections
demonstrated positive [
124I]FIAU-PET/CT signals in the sites of concern at two hours after radiopharmaceutical administration.
No adverse reactions with FIAU were observed. Conclusions/Significance. [
124I]FIAU-PET/CT is a promising new method for
imaging bacterial infections.
Citation: Diaz LA Jr, Foss CA, Thornton K, Nimmagadda S, Endres CJ, et al (2007) Imaging of Musculoskeletal Bacterial Infections by [
124I]FIAU-PET/
CT. PLoS ONE 2(10): e1007. doi:10.1371/journal.pone.0001007
INTRODUCTION
Conventional anatomic imaging techniques such as magnetic
resonance imaging (MRI) and computed tomography (CT) are
incapable of reliably distinguishing infection from sterile inflam-
mation. Previous radiopharmaceutical-based imaging techniques
for infection are indirect, for example by relying on the accumula-
tion of
99mTc- or
111In-tagged leukocytes at infectious sites rather
than on detection of the infectious agent per se.[1,2] Recently, the
ability to image bacterial infection directly with radiolabeled
antibiotics and peptides directed to specific organisms has been
studied, but clinical use has been limited, in part because of
suboptimal specificity or sensitivity.[3–6]
We were initially interested in developing an imaging agent for
in vivo monitoring of a live bacterial-based cancer therapeutic agent
named Clostridium novyi-NT (C. novyi-NT).[7–9] During our
investigations, we found that 1-(29-deoxy-29-fluoro-b-D-arabino-
furanosyl)-5-iodouracil (FIAU) was a substrate for the native
thymidine kinase (TK) from a wide variety of bacteria, including
C. novyi-NT. When [
125I]FIAU (radiolabeled, or rFIAU) was used
as an imaging tracer, it was possible to visually localize a variety of
suppurative bacterial infections.[10]
We speculated that radiolabeled analogs of FIAU could also be
used to image active bacterial infection in humans. Some of the
most challenging types of infections are those involving the
musculoskeletal system. These infections can be particularly
difficult to diagnose because non-specific symptoms, such as pain,
are frequently related to arthritis, trauma, recent surgery, or
aseptic loosening of a prosthetic joint.[11] Standard radiographs
are of limited value for diagnosis because of the paucity of reliable
diagnostic features. Magnetic resonance imaging is not widely used
because prostheses or fixation interferes with the quality of the
study and the signals are non-specific. Various radionuclide scans
have not always demonstrated sufficient sensitivity or specificity for
musculoskeletal infections.[12] For example, according to one
meta-analysis of imaging of potentially infected feet in 2,889
diabetic patients from 50 studies,
99mTc-tagged leukocytes demon-
strated a sensitivity of 86% and specificity of only 84%.[13]
Positron emission tomography with FDG-PET has also been
used.[14] The test relies on the detection of inflammatory cells
with an increased glucose uptake in areas of infection. Various
authors have demonstrated accuracy ranging from 47% to
95%.[15–17] Thus, even after a patient undergoes several imaging
and laboratory evaluations, definitive evidence to rule in or out an
infection is often elusive.
In the current study, we used a combination of [
124I]FIAU-
positron emission tomography and CT ([
124I]FIAU-PET/CT) to
test a small number of patients with suspected musculoskeletal
infections. We found that [
124I]FIAU successfully detected
bacterial lesions in all eight patients who were subsequently shown
to have clinically significant musculoskeletal bacterial infections.
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Patients
Eight subjects with proven or suspected musculoskeletal infections
and one healthy control from Sinai Hospital (Baltimore, Maryland)
or The Johns Hopkins Medical Institutions (Baltimore, Maryland)
were enrolled based on predefined eligibility criteria. Both institu-
tions are teaching and tertiary care hospitals and are major referral
sitesforpatientswith bone,joint andprostheticinfections.Thisstudy
was approved by the Institutional Review Boards (IRBs) of Johns
Hopkins and Sinai Hospitals. All subjects were enrolled with signed
written informed consent in accordance with the regulations of both
IRBs. Case histories and tables have excluded non-pertinent data
(i.e. age and gender) of individual patients to protect the identity of
our subjects. Additional demographic data is available upon request.
Study Procedure
All patients underwent a thorough screening program for the
presence of infectious symptoms including a review of the medical
history, physical findings, results of blood tests, plain-film
radiography and [
99mTc]MDP bone scan (when clinically in-
dicated). In summary, patients were eligible if they were 18 years
or older with a high suspicion of bacterial cellulitis or infections of
the musculoskeletal system. Patients with suspected infections of
the gastrointestinal tract were excluded as were those with prior
thyroid abnormalities, transplanted solid organs, liver disease, or
human immunodeficiency virus (HIV) infection. High doses of
FIAU administered for several weeks have been shown to induce
lactic acidosis and liver failure. To avoid a possible deleterious
drug interaction, we therefore excluded patients on medications
associated with lactic acidosis (e.g., Metformin).
Patients were intravenously administered 74 MBq (2 mCi) of
[
124I]FIAU (SA 8,596-13,979 Ci/mmol, avg. 11,21961,949
Ci/mmol ) and were imaged by PET/CT without intravenous
(IV) or oral contrast at two hours after injection. Four patients
were also imaged at 24 hours post injection (indicated in the text).
Six of eight patients underwent surgery for management of
possible musculoskeletal infections and tissues removed at surgery
provided material for cultures upon which their diagnoses were
based. Albumin, total bilirubin, alkaline phosphatase, total protein,
alanine aminotranferease, aspartate aminotransferase, and thyroid
stimulating hormone levels, and prothrombin time were obtained
just prior to and two weeks after [
124I]FIAU injection.
Thyroid Protection
To limit radiation exposure of iodine-concentrating thyroid tissue
that could result from the formation of free [
124I]iodide from the
metabolism of [
124I]FIAU, patients were given potassium iodide
tablets, 130 mg orally once a day, beginning 1 hour before
[
124I]FIAU administration and for a total of 8 doses.
[
124I]FIAU synthesis, purification and quality control
The synthesis of [
124I]FIAU was adapted from Jacobs et al.[18]
Radiosynthesis of [
124I]FIAU according to good manufacturing
practice (GMP) was preceded by the development of standard
operating procedures (SOPs). The GMP protocol was validated
through three successful radiosyntheses, each of which conformed
to all stipulations of the SOP. Briefly, 40 mg of 1-(29-fluoro-29-
deoxy-1-b-D-arabinofuranosyl)-uracil (FAU) precursor (ABX,
Radeberg, Germany) was added to a 0.3 mL glass v-vial
containing a Teflon-lined cap. Between 10 and 20 mCi (370–
740 MBq) of [
124I]NaI (Eastern Isotopes, Sterling, VA) in 30 mLo f
0.02 M NaOH was then added to the vial, to which was added
100 mLo f2M HNO3. The cap was sealed tightly and the reaction
was heated to 115uC for 45 min. Following quenching with 100 mL
of 0.1 M NH4OH, [
124I]FIAU was purified by HPLC using an
Alltech Absorbosil RP C18 (25064.6 mm) column eluted with 10%
ethanol in 50 mM NaH2PO4, pH 5.3, at a flow rate of 1 mL/min.
The absorbance at 254 nm and the gamma radiation were
simultaneously monitored and recorded. The collected product
was diluted with four volumes of 0.9% NaCl, passed through
a 0.22 mm syringe filter and collected into a sterile, pyrogen-free
evacuated vial. Three small aliquots of the radiopharmaceutical
solution were then taken to assess the radiochemical purity
(avg. 99.261.3%), radiochemical yield (avg. 45.6619.2%), specific
radioactivity (8,596–13,979 Ci/mmol, avg. 11,21961,949 Ci/
mmol), chemical purity (avg. 0.3960.35 mg/mL of FAU and
0.09060.004 mg/mL of FIAU) and chemical identity (via HPLC
co-injection with an FIAU standard) (figure S1).
Microbial sterility was assessed by direct inoculation of 100 mL
of radiopharmaceutical solution into Trypticase Soy Broth and
Fluid Thioglycolate Medium vials (Becton Dickenson), followed by
aerobic incubation at either 22.5uCo r3 2 . 5 uCf o rt w ow e e k s .T h e
presence of pyrogens was assessed with a Bacterial Endotoxin Test
(CharlesRiver,Wilmington,MA).Nopyrogensweredetectedinany
of the radiopharmaceutical doses (#16 USP Endotoxin Unit/mL).
PET/CT Imaging and Analysis
Patients received an intravenous injection of 74 MBq (2 mCi) of
[
124I]FIAU. Whole body PET/CT images were acquired at
2 hours and 24 hours (where indicated) post radiotracer admin-
istration using a Discovery LS instrument (General Electric
Medical Systems). The Discovery LS allows simultaneous
acquisition of 35 transaxial images with a slice thickness of
4.25 mm per bed position for the PET images. Typically, six or
more bed positions are used for a whole-body study. Transaxial
image resolution is approximately 4.5 mm in full width at half
maximum. The field of view and pixel size of the reconstructed
PET images are 50 cm and 3.91 mm, respectively. This imaging
device also allows multi-detector-row helical CT. Whole-body CT
images were acquired over 37 seconds. The technical parameters
for the CT portion of the examination were as follows: a detector-
row configuration of 465 mm, a pitch of 6:1 (high-speed mode),
a gantry rotation time of 0.8 seconds, a table speed of 30 mm per
gantry rotation, 140 kVp, and 40–120 mA (depending on body
weight). A whole-body emission PET scan for the same length of
coverage was performed, with a 5-min acquisition per bed
position. Attenuation-corrected PET images were reconstructed
with an iterative reconstruction ordered-subset expectation
maximization (OS-EM) algorithm. The 5-mm-thick transaxial
CT images were reconstructed at 4.25-mm intervals for fusion
with the transaxial PET images. CT, PET, and fused PET/CT
images were then generated on a computer workstation. DICOM
images were imported into Analyze 7.0 (Mayo Clinic Foundation,
Rochester, MN). Regions of interest were drawn manually on 2–4
slices and the activity concentration was determined. Standardized
uptake values (SUV) were normalized to lean body mass using
a formula that accounts for age, height, and body weight.[19]
RESULTS
Imaging of Infections
Only subjects with symptoms suggestive of active musculoskeletal
infections were recruited into this study. No patient had received
antibiotics within the three weeks prior to imaging. A brief clinical
description of each patient and results of the [
124I]FIAU scan are
summarized in table 1 and discussed in detail below. The first
Imaging Infections with rFIAU
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injection of [
124I]FIAU and showed similar results at both time
points. Therefore, all subsequent patients were only scanned at
2 hours. All subjects with confirmed infections had positive
[
124I]FIAU uptake within the anatomical site of interest. The
presence of infection was confirmed by intraoperative surgical
histological or culture data from the affected tissues. The control
subject and patient # 2 had negative scans and neither had clinical
evidence of infection at the time of imaging.
Patient 1 had a history of non-insulin dependent diabetes and
a right total knee replacement, presented with a painful and
swollen right knee. Synovial fluid aspirated from the replaced knee
prior to imaging revealed a white blood cell count (WBC) of
11,700 cells/dL with cultures that were positive for methicillin-
sensitive Staphylococcus aureus (MSSA). A C-reactive protein (CRP)
level was elevated at 55 mg/dL (normal value ,0.5 mg/dL).
[
124I]FIAU PET/CT imaging at 2 and 24 hours showed intense
signal within the right knee (figure 1a). The patient underwent
surgery and a grossly purulent prosthetic joint was removed and
a spacer was placed. Cultures from surgery revealed methicillin-
resistant Staphylococcus aureus (MRSA).
Patient 2 suffered from a right hip replacement that had been
recurrently infected, requiring multiple revision surgeries. The
patient had a normal peripheral WBC count and a CRP value of
8.9 mg/dL. At the time of presentation they had erythema and
pain overlying the right hip joint, which was presumed to be
a recurrent infection. Her [
124I]FIAU PET/CT scan was negative.
At the time of imaging, the patient was scheduled for surgery.
However, it was later decided by the attending orthopaedic
surgeon that the overlying erythema was most likely secondary to
an abrasion from a brace that the patient wore. Symptoms
spontaneously resolved without surgery or antibiotics.
Table 1. Patient Characteristics
..................................................................................................................................................
# Site of Concern Pre-surgical Diagnosis Post-Surgical Diagnosis Culture Results
CRP
{
(mg/dL) rFIAU Scan
2 hour 24 hour
1 Right knee Septic arthritis Septic Arthritis MRSA 55.0 Positive Positive
2 Right hip Septic arthritis No Infection* ND 8.9 Negative Negative
3 Left hip Septic prosthesis Septic prosthesis MRSA 80.1 Positive Positive
4 Right knee Septic arthritis Septic Arthritis MRSA 51.0 Positive Positive
5 Right tibia Osteomyelitis Osteomyelitis Proteus mirabilis, gram positive cocci 9.5 Positive ND
6 Left tibia Osteomyelitis Osteomyelitis No growth 5.3 Positive ND
7 Left lower extremity Cellulitis No Surgery E. faecalis, MSSA, psuedomonas sp.,
E.coli and Proteus sp.
ND Positive ND
8 Left knee Septic arthritis Necrotizing septic arthritis MRSA 150.0 Positive ND
9 Control Control Control ND ND Negative ND
{Normal C-reactive protein (CRP) levels: ,0.5 mg/dL
*Clinical symptoms concerning for infection resolved without antibiotics or surgery-no infection was diagnosed
MRSA-Methicillin-resistant Staphylococcus aureus, MSSA-Methicillin-sensitive Staphylococcus aureus
ND-Not Done
doi:10.1371/journal.pone.0001007.t001
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Figure 1. [
124I]FIAU signal in established infections as imaged by PET/CT: Fused PET and CT images, taken at 2 hours after radiotracer
administration, are shown for the following cases. (a) septic arthritis (right knee, Patient 1), (b) septic arthritis (right knee, Patient 4), (c)
osteomyelitis (left distal tibia, Patient 5), (d) cellulitis (left lower extremity, Patient 6), (e) necrotizing septic arthritis (left knee, Patient 8).
doi:10.1371/journal.pone.0001007.g001
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PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1007Patient 3 presented with a left total hip prosthesis that was painful
and warm. CRP was 80.1 mg/dL. The [
124I]FIAU PET/CT
images showed a positive signal at the junction of the left femoral
and acetabular component at 2 and 24 hours. The patient
underwent surgical irrigation and debridement and was noted to
have multiple areas of infection within the soft tissue that, when
cultured, revealed MRSA.
Patient 4 had a history of chronic MRSA osteomyelitis involving
the right knee requiring multiple surgeries. At the time of imaging,
the CRP value was 51.0 mg/dL. The [
124I]FIAU PET/CT scan
demonstrated high signal at 2 and 24 hours within the right knee
(figure 1b). Subsequent cultures from the knee demonstrated
persistent MRSA.
Patient 5 suffered from a painful and infected non-union fracture
of the right tibia as the result of a motor vehicle accident. At the
time of imaging, the CRP value was 9.5 mg/dL. The [
124I]FIAU
PET/CT scan demonstrated high signal at 2 hours localized to the
lateral aspect of the right tibia (figure 1c). The patient underwent
a right proximal tibial debridement and open reduction internal
fixation. Cultures from this necrotic material revealed Proteus
mirabilis with numerous gram-positive cocci and a few gram-
negative bacilli. Subsequent cultures from the knee demonstrated
persistent MRSA.
Patient 6 had a longstanding history of osteomyelitis in her left
distal tibia. The CRP value at the time of imaging was 5.3 mg/dL.
The [
124I]FIAU PET/CT scan showed a positive signal at 2 hours
in the distal left tibia (figure 1d). They subsequently underwent
debridement of this lesion with insertion of calcium-phosphate
beads impregnated with antibiotics. Culture results turned out to
be negative, but biopsy at the time of culture was positive for
chronic inflammation consistent with infection.
Patient 7 had a history of non-insulin dependent diabetes mellitus
had been suffering from recurrent venous stasis ulcers of the left
lower extremity for a few years following varicose vein stripping.
The [
124I]FIAU PET/CT scan was positive within an ulcer of the
left lower extremity. Cultures from this ulcer revealed multiple
organisms including Enterococcus faecalis, Staphylococcus aureus,
Pseudomonas aeruginosa and Proteus mirabilis.
Patient 8 presented with swollen and painful left knee suspicious
for infection. The CRP was 150.0 mg/dL. An intense signal was
found within the left knee on [
124I]FIAU PET/CT imaging
(figure 1e). They were found to have necrotizing MRSA
osteomyelitis of the proximal tibia.
Patient 9 had a history of osteoarthritis and prior left total knee
replacement surgery. They were placed in this study as a normal
control and to determine the normal body biodistribution for
[
124I]FIAU. The [
124I]FIAU PET/CT study was negative in the
normal and prosthetic knee despite the presence of documented
degenerative arthritis in both of these joints (figure S2).
Whole body biodistribution
The biodistribution of [
124I]FIAU in humans has not been
described. Jacobs et. al. reported the lack of [
124I]FIAU
penetration through the blood-brain barrier (BBB) in man, but
whole body distribution was not determined.[18] We measured
standardized uptake values (SUVs) in tissues from patients who
underwent [
124I]FIAU PET/CT imaging when possible (table 2).
Because of renal excretion of [
124I]FIAU, the contents of the
urinary bladder accounted for the largest fraction of signal.
Muscle, liver and kidneys were also locations of significant
[
124I]FIAU accumulation. Lungs and brain exhibited very little
signal, while the heart, spine and sacral marrow showed modest
uptake. Some uptake in the liver, pancreas, heart, muscle, and
brain was expected due to FIAU phosphorylation by high
expression levels of TK2, a mitochondrial enzyme more similar
to bacterial thymidine kinases than the major cytoplasmic kinase
(TK1).[20,21] Similar results have been described in radiolabeled
FIAU studies of experimental animals.[22]
Safety in humans
FIAU was developed in the 1990’s as a potent anti-viral agent with
promising results in early clinical trials of patients suffering from
chronic hepatitis B infections. This drug had proved to have very
serious toxicity, first described in 1995, when multiple study
subjects developed severe mitochondrial toxicity that led to
fulminant hepatic failure and death.[23] These clinical trials used
daily doses over the course of weeks that were thousands of times
greater than the dose we used as a one-time injection of radiotracer.
Patients in those trials who received FIAU for less than 4 weeks with
a cumulative doseof less than 200 mghad no clinical or biochemical
evidence of toxicity. We thereby conservatively estimated that the
‘‘no-effect dose’’ of FIAU would be on the order of 0.1 mg/kg per
administration. At the specific activities achieved in our radio-
syntheses, doses of FIAU 300,000 times less than the no-effect dose
were administered to the patients imaged in the current study.
Accordingly,wedidnotexpectanytoxicity,butasaprecaution,only
patients with normal liver function who were not taking any
potentially hepatotoxic medications were allowed to participate. To
confirm the absence of hepatotoxicity, six of the patients had
laboratory values evaluated at baseline and at least 4 weeks after
radiotracerinjection.Thesewerewithinnormallimitsinallcases.All
subjects tolerated intravenous injections of [
124I]FIAU without any
evidence of any adverse reactions.
DISCUSSION
Positive cultures, whether of tissue or blood, are the gold standard
for the diagnosis of infection. However, such tests are often
invasive and do not always accurately reflect the location and
extent of the disease. Imaging is noninvasive and unencumbered
by sampling error, and can provide sensitive information about
infection location that may enable rapid diagnosis, facilitate
monitoring and therapy. Unfortunately, traditional imaging
techniques for infection are burdened with low specificities
because they detect radiographic changes associated with infection
but not the infectious agent itself.
Table 2. [
124I]FIAU Distribution
......................................................................
Tissue 2 Hour 24 Hour
n Mean SUV SD n Mean SUV SD
Brain 3 0.83 0.30 0 NA NA
Lung 5 0.77 0.18 1 0.66 NA
Heart 3 1.77 0.27 1 1.12 NA
Liver 5 8.11 2.56 1 2.88 NA
Spleen 4 2.35 0.26 1 1.59 NA
Kidney 6 15.34 10.84 1 4.91 NA
Small Intestine 6 2.36 0.73 2 1.54 0.51
Large Intestine 6 2.10 0.81 2 1.37 0.23
Muscle 7 2.01 0.56 3 1.60 0.32
Bone 7 2.06 0.52 3 1.98 0.59
Bladder 7 51.02 24.29 1 23.01 NA
Blood 4 3.08 0.44 1 1.66 NA
doi:10.1371/journal.pone.0001007.t002
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When FIAU is phosphorylated by thymidine kinase (TK), it is
selectively trapped within cells that express this enzyme. When
coupled with a radioisotope, radiolabeled FIAU (rFIAU) can be
detected using SPECT or PET to localize TK-expressing cells in
humans. FIAU is an excellent substrate for viral TKs, especially
from the Epstein-Barr virus (EBV), and has been used to track the
expression of viral TKs encoded by gene therapy vectors in
vivo.[24] rFIAU is attractive for such applications because the
major human thymidine kinase (TK1) does not efficiently use
FIAU as a substrate.
As noted in the Introduction, we became interested in the ability of
rFIAU to act as a substrate for bacterial TKs as a result of our
preclinical experience with anaerobic, tumorolytic bacteria. The
current study was designed to test the potential utility of
[
124I]FIAU in musculoskeletal infections. Infections of prosthetic
joints can be difficult to differentiate from trauma, prosthetic
loosening, or non-infectious inflammatory conditions. Many
commonly used imaging approaches fail to achieve adequate
diagnostic specificity in this context because they target in-
flammation rather than infection. Because rFIAU is incorporated
into bacteria rather than inflammatory cells, it should be specific
for the infectious process.
There have been other attempts to image bacteria directly by
methods that employed radiolabeled immunoglobulins, peptides
or antibiotics.[5,6,25] [
99mTc]Ciprofloxacin has been proffered as
a selective bacterial imaging agent, taking advantage of differences
between bacterial and human DNA gyrase.[26] However, none of
these methods have gained widespread clinical use, partly due to
problems in sensitivity or specificity or because the agents possess
suboptimal pharmacokinetic properties.[27,28] Thus, there is an
urgent need to develop other modalities for imaging bacterial
infections in humans.
In this study, eight patients who were imaged by [
124I]FIAU
PET/CT had positive scans prior to microbiologic or pathological
confirmation of infection. Our patient population averaged
59 years of age, so that concurrent degenerative arthritis was
often present. The clinical diagnosis of osteoarthritis was
specifically documented in Patient 9, our uninfected control.
The negative imaging result for this patient demonstrated that
[
124I]FIAU PET/CT can discriminate between infections and
inflammation; more patients would have to be studied to
determine the generality of this distinction. We also demonstrated
that infections in septic native joints, in prosthetic joints and within
soft tissues can be imaged with [
124I]FIAU PET/CT. Further-
more, we attempted to correlate these findings with traditional
markers of inflammation such as CRP, which varied widely. For
example, Patients 4 and 3 had CRP levels of 51 and 80.1,
respectively, with positive imaging studies. Patient 6 had a positive
imaging study with a CRP level of only 5.3, attesting to the limited
extent to which traditional blood tests can be used to assess
infection.
Gram-positive organisms are the most common causes of
periprosthetic or joint and bone infections.[29] In the present
study, various gram-positive (staphylococci sp, enterococci sp), as well as
gram-negative (proteus sp, E.coli sp, pseudomonas sp) organisms were
identified. Interestingly, in one patient (Patient 6) with proven
chronic infection no organism was cultured but the FIAU test was
clearly positive. This may portend the clinical importance and
utility of this new diagnostic test.
However, the current study clearly has several limitations. First,
though all patients with infections were identified, this is a pilot
study and we have no information as to the sensitivity or specificity
of rFIAU imaging in infection. We also do not know how this
approach may compare to other modalities, such as MR imaging
or the current radiopharmaceutical-based methods of gallium or
tagged WBC scanning. We suspect, however, that the rFIAU
technique will be more sensitive as there should not be
confounding signal from sterile inflammation. Second, we tested
only one patient with a non-infectious inflammatory process as
a control. Third, the biodistribution analyses showed some
radiotracer accumulation within visceral organs, which will likely
limit its sensitivity for infections in these regions. Conversely, there
was minimal uptake in lungs and brain, making these very
attractive sites for future studies. Bilaterally equivalent anatomic
organs (such as those of the limbs) were found particularly suitable
for [
124I]FIAU imaging because the contralateral site provides an
excellent internal control.
One of the unexpected observations made in the current study
was that high signal-to-noise ratios were achieved within two hours
of [
124I]FIAU in patients. This is in contrast to studies with
[
124I]FIAU in mice, which required 16 to 24 hours to obtain
optimal images.[10] The difference is likely due to the much
greater size of humans compared to mice, permitting easier
distinction between localized sites of infection and other sources of
signal. In addition to this ability to image rapidly, [
124I]FIAU can
be used soon after surgery, as demonstrated in Patient 6. In
contrast, [
99mTc]Ciprofloxacin tended to provide false positive
studies if imaging was performed within 6 months of sur-
gery.[30,31] [
99mTc]Ciprofloxacin also was associated with high
radiopharmaceutical uptake in sterile inflammatory or degenera-
tive conditions.[27] The [
124I]FIAU preparation and imaging
protocol are much simpler than those for the current clinical
standard,
99mTc-tagged leukocytes. Tagged leukocyte scans must
often be coupled with a bone marrow imaging study to generate
acceptable specificity.[32] Despite these potential advantages of
[
124I]FIAU, larger studies will be required to demonstrate its true
sensitivity and specificity and its relative strengths and weaknesses
over other imaging modalities. [
124I]FIAU has recently become
commercially available and therefore should be relatively simple to
test as an imaging agent for various infections in the US.
In summary, we present a new method to image bacterial
infection in human subjects. Although we have focused on
musculoskeletal bacterial infections in the current pilot study,
efforts to extend this technique to infections in other anatomical
sites and other organisms that possess a suitable thymidine kinase
are underway. Targeting microorganismal thymidine kinase with
radiolabeled nucleoside analogs such as FIAU provides a unique
approach to the non-invasive diagnosis and therapeutic monitor-
ing of infection.
SUPPORTING INFORMATION
Figure S1 (A) The chemical structure of [
124I]FIAU. (B) HPLC
chromatogram, simultaneously monitored by A254 spectroscopy
and gamma counting.
Found at: doi:10.1371/journal.pone.0001007.s001 (0.15 MB PPT)
Figure S2 [
124I]FIAU signal in a healthy subject without
infection as imaged by PET/CT: Fused PET/CT images 2 hours
after [
124I]FIAU injection in the axial and coronal views. The
patient was a healthy control with a left knee prosthesis. No
significant signal was noted in either knee.
Found at: doi:10.1371/journal.pone.0001007.s002 (0.30 MB PPT)
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